Translational progress on tumor biomarkers

Thoracic Cancer

Hongwei Guo³  Xiaolin Zhou³  Yi Lu³  Liye Xie³  Qian Chen³  Evan T. Keller⁴  Qian Liu²  Qinghua Zhou¹ 

[1] Lung Cancer Center, Huaxi Hospital, Sichuan University, Chengdu, China;Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute, Tianjin Medical University General Hospital, Tianjin, China;Key Laboratory of Longevity and Aging-Related Diseases, Ministry of Education, Nanning, China;Department of Urology and Pathology, School of Medicine, University of Michigan, Ann Arbor, Michigan, USA

关键词: Targeted therapy;    translational medicine;    tumor biomarkers;   

DOI  :  10.1111/1759-7714.12294

来源: Wiley

【 摘 要 】

Abstract

There is an urgent need to apply basic research achievements to the clinic. In particular, mechanistic studies should be developed by bench researchers, depending upon clinical demands, in order to improve the survival and quality of life of cancer patients. To date, translational medicine has been addressed in cancer biology, particularly in the identification and characterization of novel tumor biomarkers. This review focuses on the recent achievements and clinical application prospects in tumor biomarkers based on translational medicine.

【 授权许可】

CC BY-NC   
© 2015 The Authors. Thoracic Cancer published by China Lung Oncology Group and Wiley Publishing Asia Pty Ltd.

Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.